Blue Owl Capital Holdings LP Invests $609,000 in COMPASS Pathways plc (NASDAQ:CMPS)

Blue Owl Capital Holdings LP bought a new stake in shares of COMPASS Pathways plc (NASDAQ:CMPS - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 161,238 shares of the company's stock, valued at approximately $609,000. Blue Owl Capital Holdings LP owned 0.24% of COMPASS Pathways at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. purchased a new position in COMPASS Pathways during the 4th quarter valued at $41,000. Flagship Harbor Advisors LLC purchased a new stake in shares of COMPASS Pathways during the fourth quarter valued at $43,000. Wealthfront Advisers LLC purchased a new stake in shares of COMPASS Pathways during the fourth quarter valued at $43,000. Conservest Capital Advisors Inc. grew its holdings in shares of COMPASS Pathways by 28.9% in the fourth quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company's stock worth $51,000 after purchasing an additional 3,000 shares during the last quarter. Finally, Simplify Asset Management Inc. purchased a new position in COMPASS Pathways in the 4th quarter worth about $54,000. Institutional investors own 46.19% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. HC Wainwright reissued a "buy" rating and issued a $45.00 price objective on shares of COMPASS Pathways in a research report on Tuesday, March 4th. Stifel Nicolaus began coverage on COMPASS Pathways in a report on Thursday, February 27th. They issued a "buy" rating and a $11.00 price target for the company. Royal Bank of Canada restated an "outperform" rating and set a $18.00 price objective on shares of COMPASS Pathways in a report on Wednesday, January 15th. Canaccord Genuity Group lowered their target price on COMPASS Pathways from $23.00 to $15.00 and set a "buy" rating for the company in a report on Friday, February 28th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of COMPASS Pathways in a research report on Friday, March 28th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $20.20.

COMPASS Pathways Stock Performance

NASDAQ CMPS traded down $0.17 on Friday, hitting $3.82. 583,172 shares of the company's stock traded hands, compared to its average volume of 790,816. The firm has a market capitalization of $354.01 million, a PE ratio of -1.74 and a beta of 2.34. COMPASS Pathways plc has a 1-year low of $2.49 and a 1-year high of $9.63. The firm's 50-day moving average price is $3.36 and its two-hundred day moving average price is $4.18. The company has a current ratio of 8.91, a quick ratio of 8.91 and a debt-to-equity ratio of 0.15.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.01). As a group, analysts expect that COMPASS Pathways plc will post -2.33 EPS for the current year.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.